循环单核细胞可预测阿普司特治疗中重度斑块状银屑病的反应
该16周开放标签研究纳入22例中重度斑块状银屑病患者,通过单核细胞流式细胞术和转录组分析,发现基线高粘附单核细胞双联体升高者更可能对阿普司特应答(P<.0001),且治疗后可显著减少含高粘附单核细胞的双联体和单核细胞-血小板聚集体。
要点
- 基线高粘附单核细胞双联体升高者阿普司特应答率更高。
- 阿普司特可减少高粘附单核细胞双联体和单核细胞-血小板聚集体。
- 单核细胞差异表达基因转录本可揭示预测临床应答的药物内表型。
核心结论
- 基线高粘附单核细胞双联体可预测中重度斑块状银屑病患者对阿普司特的临床应答。
- 阿普司特治疗可降低循环中高粘附单核细胞双联体和单核细胞-血小板聚集体的水平。
研究设计与样本
- 16周开放标签研究,纳入22例中重度斑块状银屑病患者,进行单核细胞流式细胞术和转录组分析。
主要发现
- 基线高粘附单核细胞双联体升高者更可能对阿普司特应答(P < .0001)。
- 高粘附单核细胞双联体升高者中82%达到PASI 50应答,而无升高者为46%。
- 治疗后观察到含高粘附单核细胞的双联体和单核细胞-血小板聚集体显著减少。
- 单核细胞差异表达基因转录本揭示了具有不同核苷酸代谢、能量代谢和分化模式的药物内表型。
关键数值与推荐
- 高粘附单核细胞双联体升高者中82%达到PASI 50,无升高者为46%。
临床怎么用
- 基线高粘附单核细胞双联体检测有望用于预测中重度斑块状银屑病患者对阿普司特的应答。
- 单核细胞精炼的基因表达分析未来可能帮助制定阿普司特治疗算法,实现个体化用药。
局限性
- 研究为开放标签设计,样本量较小(22例),需进一步研究验证单核细胞生物标志物的临床实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monocytes play a critical role in the inflammation associated with psoriasis, and their abnormalities have been reported as biomarkers of cardiovascular event risk, a psoriasis comorbidity. Monocytic cells in chronic inflammatory disorders express elevated levels of cAMP phosphodiesterase. Restoring cAMP levels using the oral cAMP phosphodiesterase-4 inhibitor, apremilast, improves clinical outcomes for a subset of patients with psoriasis. We asked whether aberrant monocyte subsets or transcriptomic pathways can function as biomarkers of psoriasis endotypes that can predict enhanced clinical responses to cAMP phosphodiesterase inhibition. A 16-week open-label study of 22 patients with monocyte flow cytometric and transcriptomic analysis was performed. Subjects with elevated hyperadhesive monocyte doublets at baseline were more likely to be responders to apremilast (P < .0001); 82% of subjects with elevated hyperadhesive monocyte doublets achieved 50% reduction in PASI compared with 46% in those without elevated doublets. We observed a significant reduction in hyperadhesive monocyte-containing doublets and monocyte-platelet aggregates, suggesting an effect of apremilast on the adhesiveness of blood monocytes during chronic inflammation. Monocyte differentially expressed gene transcripts predictive of clinical response uncovered pharmacoendotypes with distinct patterns of nucleotide metabolism, energetics, and differentiation. Further study to understand the basis of drug responsiveness and to develop an apremilast psoriasis treatment algorithm using monocyte-refined gene expression is required to validate and become practical in clinical use, offering patients a test that personalizes their likelihood of clinical response.
引用
- Larson EL, DeMeo DP, Young AB, et al. Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with Apremilast. J Invest Dermatol. 2024. PMID: 38431222. doi:10.1016/j.jid.2024.01.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。